• Explore /
  • Poster
  • / A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.

A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.

Abstract Poster

Authors

Hendrik-Tobias Arkenau

Hendrik-Tobias Arkenau

Sarah Cannon Research United Kingdom, London, United Kingdom

Hendrik-Tobias Arkenau , Anas Gazzah , Ruth Plummer , Sarah Patricia Blagden , Gabriel Mak , Jean-Charles Soria , Alastair Greystoke , Ivana Rizzuto , Debra Rogan , Jolly Mazumdar , Kevin Laubscher , Kurt R Auger , Lisa S Swartz , Maria L Mattern , Noelia Nebot , Rajendra P Singh , Ronald Alan Fleming , Li Yan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Signal Transduction

Clinical Trial Registration Number

NCT01938443

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2593)

DOI

10.1200/jco.2015.33.15_suppl.2593

Abstract #

2593

Poster Bd #

309

Abstract Disclosures

Similar Posters

First Author: Dejan Juric

First Author: Michael S. Gordon

First Author: Filip Janku

First Author: Christian K. Kollmannsberger